EVEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EVEX (EVEX).
Estrogen receptor agonist; binds to and activates nuclear estrogen receptors, leading to gene transcription and cellular effects in target tissues.
| Metabolism | Hepatic metabolism primarily via CYP3A4 to estrone, estradiol, and other metabolites; undergoes enterohepatic recirculation. |
| Excretion | Primarily hepatic metabolism with renal excretion of metabolites; approximately 60% of a dose is excreted in urine as conjugates (glucuronides and sulfates) and 30% in feces via biliary elimination. Less than 5% is excreted unchanged in urine. |
| Half-life | Terminal elimination half-life is 12-24 hours, with a mean of approximately 18 hours. Due to significant enterohepatic recirculation, the half-life may be prolonged in patients with hepatic impairment or when administered with drugs that inhibit recirculation. |
| Protein binding | Approximately 90-95% bound to plasma proteins, primarily albumin and estrogen-binding globulin. |
| Volume of Distribution | Apparent volume of distribution is approximately 4-6 L/kg, indicating extensive distribution into tissues, including adipose tissue and reproductive organs. |
| Bioavailability | Oral: 40-60% (due to first-pass metabolism); Transdermal: 10-20% (dose-dependent, with higher absorption from gel than patch); Intravenous: 100%. |
| Onset of Action | Oral: 1-4 hours; Intravenous: 15-30 minutes; Transdermal: steady-state achieved after 2-3 applications, with initial effects within 4-12 hours. |
| Duration of Action | Oral: 24 hours (once-daily dosing); Transdermal: approximately 7 days (weekly patch); Intravenous: duration depends on dose and infusion rate, typically 24-48 hours for a single dose. |
0.625-1.25 mg orally once daily; or 0.3-0.625 mg vaginally once daily for 21 days with 7 days off.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment required; use with caution in severe renal impairment (GFR <30 mL/min) due to potential accumulation of metabolites. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use. |
| Pediatric use | Not indicated for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Start at lowest effective dose (0.3 mg/day) and titrate slowly; monitor for thromboembolic events and endometrial hyperplasia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EVEX (EVEX).
| Breastfeeding | Estradiol is excreted in human breast milk with an M/P ratio of approximately 0.5. It may reduce milk production and quality. Use during breastfeeding is not recommended; if necessary, monitor the infant for signs of estrogen exposure (e.g., vaginal bleeding in female infants, breast enlargement). |
| Teratogenic Risk | Estradiol, the active component of EVEX, is contraindicated in pregnancy. First trimester exposure is associated with a risk of congenital anomalies, including cardiovascular and limb defects. Second and third trimester exposure may cause feminization of male fetuses and potential long-term reproductive tract abnormalities. Use is not recommended at any stage of pregnancy. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer in postmenopausal women with an intact uterus. Estrogen-alone therapy increases the risk of stroke and deep vein thrombosis. Estrogen plus progestin therapy increases the risk of stroke, deep vein thrombosis, pulmonary embolism, myocardial infarction, and breast cancer.
| Common Effects | Headache Nausea Breast pain Abdominal cramp Bloating Vaginal spotting Vomiting |
| Serious Effects |
Undiagnosed abnormal genital bleeding; known or suspected pregnancy; known or suspected estrogen-dependent neoplasia; active thromboembolic disorder or history of such; known hypersensitivity to estrogens or any component of the formulation; severe hepatic impairment; known or suspected history of breast cancer.
| Precautions | Risk of endometrial hyperplasia/carcinoma; cardiovascular events (stroke, MI, venous thromboembolism); breast cancer; dementia; gallbladder disease; hypercalcemia; fluid retention; elevated blood pressure; hypertriglyceridemia; severe hepatic impairment; hereditary angioedema; hypersensitivity reactions; caution in patients with known risk factors for thromboembolic disorders. |
Loading safety data…
| Fetal Monitoring | If inadvertent exposure occurs during pregnancy, monitor fetal growth and anatomy via ultrasound. No routine monitoring is required in non-pregnant patients. In lactating women, observe infant for adverse effects. |
| Fertility Effects | Estradiol can suppress gonadotropin secretion, potentially inhibiting ovulation and reducing fertility. Effects are reversible upon discontinuation. Use for contraception is not recommended due to insufficient efficacy. |
| Food/Dietary | No clinically significant food interactions. Avoid grapefruit juice only if systemically absorbed estrogens are a concern; for vaginal ring, systemic absorption is minimal. |
| Clinical Pearls | EVEX (estradiol vaginal ring) delivers continuous low-dose estradiol locally. Avoid use in women with undiagnosed vaginal bleeding, known/suspected breast cancer, or active thromboembolic disorders. Ring must be replaced every 90 days. Assess need for progestin if uterus intact due to endometrial hyperplasia risk. |
| Patient Advice | Insert ring high into vagina; it may be removed for sexual intercourse (rinse and reinsert within 60 minutes). · Replace ring every 90 days; do not leave out for more than 60 minutes. · Report irregular vaginal bleeding, breast lumps, or signs of thromboembolism (leg pain, chest pain, dyspnea). · Do not use oil-based lubricants (may degrade ring); water-based lubricants are safe. · Store at room temperature, away from heat and direct sunlight. |